Houston JB - Search Results

1

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Among authors: houston jb. Drug Metab Dispos. 2002 Dec;30(12):1512-22. doi: 10.1124/dmd.30.12.1512. Drug Metab Dispos. 2002. PMID: 12433827

2

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Among authors: houston jb. Drug Metab Dispos. 2003 Sep;31(9):1108-16. doi: 10.1124/dmd.31.9.1108. Drug Metab Dispos. 2003. PMID: 12920166

3

Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.

Houston JB, Galetin A. Houston JB, et al. Drug Metab Rev. 2003 Nov;35(4):393-415. doi: 10.1081/dmr-120026870. Drug Metab Rev. 2003. PMID: 14705868 Review.

4

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Galetin A, et al. Among authors: houston jb. Drug Metab Dispos. 2004 Dec;32(12):1411-20. doi: 10.1124/dmd.104.000844. Epub 2004 Sep 1. Drug Metab Dispos. 2004. PMID: 15342470

5

Modelling atypical CYP3A4 kinetics: principles and pragmatism.

Houston JB, Galetin A. Houston JB, et al. Arch Biochem Biophys. 2005 Jan 15;433(2):351-60. doi: 10.1016/j.abb.2004.09.010. Arch Biochem Biophys. 2005. PMID: 15581591 Review.

6

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB. Galetin A, et al. Among authors: houston jb. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784650 Free article.

7

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.

Galetin A, Burt H, Gibbons L, Houston JB. Galetin A, et al. Among authors: houston jb. Drug Metab Dispos. 2006 Jan;34(1):166-75. doi: 10.1124/dmd.105.006874. Epub 2005 Oct 12. Drug Metab Dispos. 2006. PMID: 16221752

8

Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.

Galetin A, Houston JB. Galetin A, et al. Among authors: houston jb. J Pharmacol Exp Ther. 2006 Sep;318(3):1220-9. doi: 10.1124/jpet.106.106013. Epub 2006 Jun 8. J Pharmacol Exp Ther. 2006. PMID: 16763093

9

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

Brown HS, Galetin A, Hallifax D, Houston JB. Brown HS, et al. Among authors: houston jb. Clin Pharmacokinet. 2006;45(10):1035-50. doi: 10.2165/00003088-200645100-00006. Clin Pharmacokinet. 2006. PMID: 16984215

10

Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. Galetin A, et al. Among authors: houston jb. Curr Drug Metab. 2007 Oct;8(7):685-93. doi: 10.2174/138920007782109805. Curr Drug Metab. 2007. PMID: 17979656 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters